Patent · US Active

Selective histone deactylase 6 inhibitors

US9956192B2 · kind B2 · utility

0Cited by

0References

25Claims

0Family size

Assignees

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS · US

Inventors

Eduardo M. Sotomayor · Tampa, US
Joel Bergman · Chicago, US
Alan P. Kozikowski · Princeton, US
Karrune V. Woan · Gainesville, US
Alejandro V. Villagra · Tampa, US

Key dates

Filing date	Aug 8, 2016
Grant date	May 1, 2018
Priority date	—
Expiry date	Aug 8, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.